HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Consumer Unit Suitors Tasked With Determining Value Of Excedrin

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.

You may also be interested in...



Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It

Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio

OTC M&A Trend May Be Result Of Too Many Large Players At The Top – Panel

A lack of competitive global scale may be one factor fueling the divestiture of OTC units by larger pharma companies

Bristol Consumer Package Will Include OTC Pravachol

Royalties from OTC Pravachol would be included in a sale of Bristol-Myers Squibb's consumer brands

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel